12:00 AM
Dec 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AC220: Additional Phase I data

Additional data from an open-label, dose-escalation Phase I trial in 76 patients showed that 12-450 mg oral AC220 resulted in a 30% overall response rate (ORR). There were 2 cases of complete remission (CR), 2 cases of CR with incomplete platelet recovery (CRp), 6 cases...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >